Baudax Bio Inc

OTC:BXRXQ

Baudax Bio, Inc. operates as a pharmaceutical company. The company is headquartered in Malvern, Pennsylvania and currently employs 80 full-time employees. The company went IPO on 2019-11-14. The firm is focused on developing and commercializing products for hospital and related acute care settings. The firm's lead product candidate is ANJESO (meloxicam) injection. ANJESO is a preferential COX-2 inhibitor that possesses analgesic, anti-inflammatory, and antipyretic activities. The injectable form of IV meloxicam, which utilizes NanoCrystal technology, increases overall drug solubility that provides a faster onset of action of meloxicam and provides a rapid treatment of acute pain. Its product pipeline includes Neuromuscular blocking agents (NMBAs), which are used as muscle paralyzing agents to facilitate intubation and surgery. The firm is developing intermediate-acting NMBA, BX1000, an ultrashort-acting NMBA, BX2000, and a reversal agent specific to its NMBAs. Its other products include Dex-IN, which is a selective alpha-2 adrenergic agonist that has sedative, analgesic, and anxiolytic properties.